GS13 - ledipasvir/sofosbuvir for 12 or 24 weeks is safe and effective in kidney transplant recipients with chronic genotype 1 or 4 Hcv infection - Colombo, M; Aghemo, A; Liu, L (J Hepatol, 2016)